On behalf of the FDA, Dr. Uri Ben-Zur and The Cardiovascular Institute would like to inform you of a recently approved drug for lowering cholesterol and treating patients with heart disease.
The brand name of the medication is Praluent ®. The generic name is alirocumab.
This drug was approved on July 24, 2015 and works to decrease levels of our body’s “bad cholesterol” also called “LDL” cholesterol. It is a second line drug for patients who cannot tolerate statin therapy or those who have not been able to lower their LDL cholesterol enough with statins.
According to the FDA, the efficacy and safety of Praluent were evaluated in five placebo-controlled trials, involving 2,476 participants exposed to Praluent. Participants taking Praluent had an average reduction in LDL cholesterol ranging from 36 to 59 percent, compared to placebo.
The most common side effects of Praluent include itching, swelling, pain, or bruising where injection is given, nasopharyngitis, and flu. Allergic reactions, such as rashes and skin discolorations can also occur.
So if you have a history of heart disease, please come visit or call us 818.986.0911, and ask us about Praluent today!
For more information visit: http://www.regeneron.com/Praluent
Uri M. Ben-Zur, M.D., F.A.C.C.
Dr. Ben-Zur is a interventional cardiologist in Tarzana and Encino. He performs Atrial Fibrillation ablations as well as Atrial Flutter Ablations. He is open from 6 AM to 3 PM 6 days a week.